Announcement of Granted Patent – substance patent for human CCR7 Antibody

We are pleased to announce that the substance patent for a functional antibody that specifically recognizes human CCR7 has been granted and published in the Japanese Patent Office.

CCR7 antibodies are expected to find applications in the treatment of autoimmune diseases and cancer.

Patent No.： Patent No. 7747395 (P7747395)
Publication number：WO2024/204440
Registration date: September 22, 2025
Title of the Invention：ANTIBODY, NUCLEIC ACID, CELL, AND PHARMACEUTICAL